|Bid||0.6500 x 1100|
|Ask||2.1300 x 1300|
|Day's Range||1.5000 - 1.6640|
|52 Week Range||0.6200 - 4.0800|
|Beta (3Y Monthly)||4.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.67|
MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today provided the following business update and letter to shareholders from the Company’s CEO, Patrick Herguth. The Company also reported it has filed its quarterly report on Form 10-Q for the period ending December 31, 2018, which is available at: www.sec.gov.
MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today announced that the U.S. General Services Administration has awarded a five-year Federal Supply Schedule (FSS) contract as a government supplier, effective January 31, 2019 with the opportunity to renew it for 15 more years. Under the contract, MYnd intends to offer Healthcare Information Technology services to federal government departments and agencies related to our Psychiatric EEG Evaluation Registry, including the Department of Defense and the United States Department of Veterans Affairs (VA) facilities nationwide.
What percentage of MYnd (to be renamed “Emmaus Life Sciences, Inc.” and referred to as “New Emmaus”) will current MYnd Analytics (“MYnd”) shareholders own upon completion of the transaction? MYnd shareholders will own 5.9% of the fully diluted shares of Emmaus post closing.
Emmaus’ commercial lead product Endari™ (L-glutamine oral powder) is FDA approved to reduce the acute complications of sickle cell disease Endari addresses a $3 billion.
While small-cap stocks, such as MYnd Analytics, Inc. (NASDAQ:MYND) with its market cap of US$7.8m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...
MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today announced that Patrick Herguth will be joining the team as Chief Executive Officer and has also been appointed to the Board of Directors. George Carpenter will assume the new role of Chief Innovation Officer.
MYnd Analytics, Inc. (MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced that it has been awarded a subcontract to incorporate its PEER report within a project to develop a suicide prevention toolkit, for the U.S. Department of Health and Human Services (HHS). George Carpenter, CEO of MYnd stated, “We are honored to be a part of this important project, which involves development of a suicide prevention tool kit for HHS. Importantly, we look forward to leveraging our expertise and the extensive data we have compiled through the PEER registry.
In fact, there are additional sectors that have just begun to gain investor interest with regard to new advancements in technology. The global big data in the healthcare market is gaining interest and this has been due to the introduction of personalized healthcare systems and demand for high-quality healthcare services. With this technology, healthcare providers are adding to their capabilities by analyzing patient behavior towards a particular treatment and diagnostic patterns, in order to provide them with customized and highly cost-effective services.
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Exact Sciences made headlines on Wednesday, announcing an agreement with Pfizer to share marketing expenses and to co-promote the company’s Colorguard colorectal ...